Pardes Biosciences, Inc. focuses on discovering, developing, and commercializing novel therapeutics. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Market Cap | 79.637 Million | Shares Outstanding | 61.734 Million | Avg 30-day Volume | 138.505 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.4 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -38.488 Million |
Price to Book Value | 0.2336 | Operating Margin | 0.0 | Enterprise Value | -206.464 Million |
Current Ratio | 30.704 | EPS Growth | 0 | Quick Ratio | 29.97 |
1 Yr BETA | 0.9072 | 52-week High/Low | 8.75 / 0.75 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 0.0 | Altman Z-Score | 4.6012 | Free Cash Flow to Firm | 0 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
WIGGANS THOMAS G CHIEF EXECUTIVE OFFICER |
|
0 | 2023-02-01 | 4 |
HENSON HEIDI CHIEF FINANCIAL OFFICER |
|
0 | 2023-02-01 | 2 |
LACY ELIZABETH H. GENERAL COUNSEL, SECRETARY |
|
0 | 2023-02-01 | 2 |
BRUSKY SEAN P. CHIEF COMMERCIAL OFFICER |
|
0 | 2023-02-01 | 3 |
KEARNEY BRIAN CHIEF DEVELOPMENT OFFICER |
|
0 | 2023-02-01 | 2 |
|
12,809,810 | 2022-12-01 | 2 | |
|
75,000 | 2022-09-14 | 2 | |
|
0 | 2022-09-14 | 2 | |
TINMOUTH BRIAN PHILIPPE CHIEF BUS. & STRATEGY OFFICER |
|
125,000 | 2022-09-14 | 1 |
|
1,363,861 | 2022-07-19 | 2 | |
|
37,500 | 2022-06-08 | 1 | |
|
37,500 | 2022-06-08 | 2 | |
|
37,500 | 2022-06-08 | 1 | |
|
37,500 | 2022-06-08 | 1 | |
|
37,500 | 2022-06-08 | 1 | |
ARNOLD LEE D CHIEF SCIENTIFIC OFFICER |
|
100,000 | 2022-02-01 | 0 |
LOPATIN URI A PRESIDENT AND CEO |
|
421,000 | 2022-02-01 | 0 |
|
0 | 2021-12-23 | 0 | |
|
0 | 2021-12-23 | 0 | |
FORESITE CAPITAL MANAGEMENT V, LLC |
|
75,000 | 2021-12-23 | 2 |
|
0 | 2021-12-23 | 0 | |
|
5,476,250 | 2021-12-23 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-03 16:29:28 -0500 | 2023-02-01 | A | 156,250 | a | 156,250 | direct | ||||||||||
2023-02-03 16:30:38 -0500 | 2023-02-01 | A | 156,250 | a | 156,250 | direct | ||||||||||
2023-02-03 16:34:50 -0500 | 2023-02-01 | A | 156,250 | a | 156,250 | direct | ||||||||||
WIGGANS THOMAS G - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-02-03 16:36:31 -0500 | 2023-02-01 | A | 562,500 | a | 562,500 | direct | |||||||||
2023-02-03 16:28:20 -0500 | 2023-02-01 | A | 156,250 | a | 156,250 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
PARDES BIOSCIENCES INC PRDS | 2023-03-24 22:15:03 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 21:45:03 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 21:15:03 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 20:45:03 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 20:15:04 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 19:45:03 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 19:15:04 UTC | 1.89 | 2.93 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 18:45:04 UTC | 1.8856 | 2.9344 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 18:15:03 UTC | 1.8856 | 2.9344 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 17:45:03 UTC | 1.8856 | 2.9344 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 17:15:03 UTC | 1.8856 | 2.9344 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 16:45:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 16:15:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 15:45:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 15:15:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 14:45:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 14:15:03 UTC | 1.8354 | 2.9846 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 13:45:03 UTC | 1.8583 | 2.7117 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 13:15:04 UTC | 1.8583 | 2.7117 | 350000 |
PARDES BIOSCIENCES INC PRDS | 2023-03-24 12:45:03 UTC | 1.8583 | 2.7117 | 500000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | PRDS | -1600.0 shares, $-1920.0 | 2022-10-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | PRDS | -3000.0 shares, $-5070.0 | 2022-12-31 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | PRDS | -1767.0 shares, $-2986.23 | 2022-12-31 | N-PORT |